1月22日晚， 微创医疗(00853)发布公告宣布，预期公司2025年年度将实现扭亏为盈，并取得净利润不低于2000万美元。 在公告中，微创医疗指出，公司预期扭亏为盈主要归因于期内收入的持续增长，尤其出海业务收入继续贡献同比约70%的高速增长，并指出虽然公司面临国 内行业政策给产品价格带来的下行压力，但受益于成本优化举措的落实，毛利率仍同比提升2-3个百分点; 与此同时公司也在持续提升经营效率，报告期内经营费用同比下降约10-11%;最后，附属公司处置也为微创医疗贡献了正向收益。 得益于盈喜利好，1月23日，微创医疗股价高开高走，早盘最高涨幅一度冲至12.84%。但其股价上攻势头只持续了不到半小时，在触高后，微创医疗股价开 始一路向下俯冲，上午收盘时的涨幅已收窄至不足4%。 从成交量来看，微创医疗当日成交量达到7706.71万股，刷新了去年10月以来的新纪录。从分时成交量分布来看，活跃交易多成交于开盘，也就是说，有不 少投资者买在了当日的"山顶"。 在利好消息"掩护"下的冲高回落 从盘面来看，自去年10月8日盘中冲高至年内高点16.28港元后，微创医疗股价便开启了一段为期2个月的震荡下跌行情。区间内，公司股价 ...

1月22日晚， 微创医疗(00853)发布公告宣布，预期公司2025年年度将实现扭亏为盈，并取得净利润不低 于2000万美元。 在公告中，微创医疗指出，公司预期扭亏为盈主要归因于期内收入的持续增长，尤其出海业务收入继续 贡献同比约70%的高速增长，并指出虽然公司面临国内行业政策给产品价格带来的下行压力，但受益于 成本优化举措的落实，毛利率仍同比提升2-3个百分点; 与此同时公司也在持续提升经营效率，报告期内经营费用同比下降约10-11%;最后，附属公司处置也为 微创医疗贡献了正向收益。 得益于盈喜利好，1月23日，微创医疗股价高开高走，早盘最高涨幅一度冲至12.84%。但其股价上攻势 头只持续了不到半小时，在触高后，微创医疗股价开始一路向下俯冲，上午收盘时的涨幅已收窄至不足 4%。 从成交量来看，微创医疗当日成交量达到7706.71万股，刷新了去年10月以来的新纪录。从分时成交量 分布来看，活跃交易多成交于开盘，也就是说，有不少投资者买在了当日的"山顶"。 在利好消息"掩护"下的冲高回落 从盘面来看，自去年10月8日盘中冲高至年内高点16.28港元后，微创医疗股价便开启了一段为期2个月 的震荡下跌行情。区间内 ...

内容概要：冠脉通路器械是经皮冠状动脉介入手术的必备耗材，其性能直接影响手术成效与并发症控制 水平。政策端，我国出台集采、创新审批、基层医疗建设等系列政策，从多维度为行业高质量发展筑牢 基础。需求端，全球及中国冠状动脉疾病患病人数稳步增长，2024年全球患者达2.2亿人、中国达2787.9 万人，且中国PCI手术渗透率与发达国家差距显著，为行业提供广阔增量空间。市场规模方面，全球冠 脉球囊扩张导管市场持续扩容，功能性球囊增速领先；中国市场呈"结构调整与高速增长并存"特征，通 用球囊受集采影响经历阶段性调整后有望回升，功能性球囊作为国产替代核心赛道增长迅猛，2024- 2028年复合年均增长率高达19.28%。竞争格局上，行业呈梯队化分布，外资主导高端市场，国产头部 企业加速突围，2024年国产冠脉球囊市场份额已达54.9%。未来，行业将沿着技术升级、国产替代深 化、基层市场扩容三大方向演进，形成"器械+服务+数据"的协同生态，驱动行业向创新普惠方向发 展。 上市企业：微创医疗（00853）、业聚医疗（06929）、乐普医疗（300003）、赛诺医疗（688108）、惠 泰医疗（688617）、蓝帆医疗（0023 ...

Core Viewpoint - The strategic importance of medical device logistics and distribution is increasingly recognized as the market for medical devices continues to expand, leading to a strong demand for specialized and efficient logistics services [1][8]. Industry Overview - Medical device logistics and distribution involves the effective transfer of medical device products from suppliers or manufacturers to medical institutions, pharmacies, or other relevant endpoints, ensuring safety, timeliness, and accuracy [2][3]. - The industry has evolved through four stages, from minimal focus during the early marketization phase to a rapid development period from 2010 to 2020, driven by increasing demand and regulatory policies [3]. Industry Policies - Recent government policies have provided strong support for the development of the medical device logistics industry, promoting standardization, efficiency, and scale [4]. - Key policies include the establishment of a risk-sharing alliance for online sales of medical devices and encouragement for wholesale companies to integrate storage and transportation resources [4]. Industry Chain - The upstream of the medical device logistics chain includes suppliers of logistics vehicles, software, medical devices, storage equipment, and packaging materials [4]. - The midstream consists of logistics service providers, which are crucial for the entire supply chain, while the downstream includes medical institutions and patients as the primary demand side [4]. Current Industry Status - The logistics total cost for medical devices in China is projected to reach 26.78 billion yuan in 2024, with a year-on-year growth of 1.88% [8]. - The logistics warehousing area is expected to be 23.58 million square meters in 2024, reflecting a 0.8% increase [8]. Market Trends - The medical device logistics industry is expected to accelerate its digital transformation and integration of intelligent technologies, utilizing IoT for real-time monitoring and big data for demand forecasting [12][14]. - Service models are evolving towards highly specialized and integrated solutions, addressing specific requirements for different categories of medical devices [14]. - The logistics network is anticipated to deepen into lower-tier cities, establishing regional distribution centers to enhance efficiency and reduce costs [15].

Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Medical (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On January 23, southbound funds increased their holdings by 1.6216 million shares of MicroPort Medical [1] - Over the past five trading days, there have been four days of net increases, totaling 7.5492 million shares [1] - In the last 20 trading days, there were 16 days of net increases, amounting to 33.0996 million shares [1] - Currently, southbound funds hold 913 million shares of MicroPort Medical, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Flash | 22 Jan 2026 21:15:10 ET │ 11 pages MicroPort Scientific (0853.HK) FY25 Profit Alert: Strong Beat CITI'S TAKE MicroPort announced a significant positive profit alert for FY25, guiding for a net profit of at least US$20mn. This represents a strong beat versus our estimate of a US$54mn loss and VA consensus of a US$57mn loss, and marks a dramatic turnaround from the US$268mn loss in FY24. The strong result is driven by a combination of sustained revenue growth (led by the 'going-abroad' business at +70 ...

1月23日，微创医疗(00853.HK)股价大幅拉升，盘中一度涨逾13.6%；截至发稿，该股涨幅有所收窄，为3.37%，报12.88港元/股。 该股涨势如此靓丽，主要得益于业绩利好刺激。 1月22日，微创医疗发布盈利预喜公告，预计2025年将实现扭亏为盈，录得净利润不低于2000万美元，2024年则净亏损约2.68亿美元。 在快速变化的市场环境以及日趋激烈的行业竞争格局下，近几年微创医疗一方面稳固在国内市场的领先份额，加速推进新产品、新技术的市场准入，确保在 国内市场的核心竞争力；另一方面，通过整合资源、发挥海外渠道优势，助力各业务板块产品快速打入海外市场，拓展国际业务版图。 不过，受持续高强度创新研发投入、业务扩张相关支出等因素影响，微创医疗曾长期陷入亏损困境。回顾过往财务数据，2020年至2024年，公司累计归母净 亏损额近16亿美元，经营压力可见一斑。 对于2025年盈利状况的显著改善，微创医疗解释称，主要得益于四大方面的积极变化： 其四，附属公司处置为公司带来正向收益，进一步改善了整体财务表现。 综上所述，在经历多年持续亏损后，微创医疗凭借积累多年的多元化业务集群优势、自主可控的核心创新能力，叠加降本 ...

消息面上，1月22日晚，微创医疗公布，预期集团截至2025年12月31日止年度将实现扭亏为盈，并取得 净利润不低于2000万美元。预期扭亏为盈主要归因于期内收入的持续增长，尤其出海业务收入继续贡献 同比约70%的高速增长；尽管中国境内行业政策给产品价格带来下行压力，受益于成本优化举措的落 实，毛利率仍同比提升2~3个百分点；于运营方面持续深化精益管理，提升经营效率，令集团经营费用 同比下降约10~11%；及附属公司处置为集团贡献正向收益。 微创医疗(00853)大涨超11%，截至发稿，涨9.39%，报13.63港元，成交额2.6亿港元。 ...

消息面上，1月22日晚，微创医疗公布，预期集团截至2025年12月31日止年度将实现扭亏为盈，并取得 净利润不低于2000万美元。预期扭亏为盈主要归因于期内收入的持续增长，尤其出海业务收入继续贡献 同比约70%的高速增长；尽管中国境内行业政策给产品价格带来下行压力，受益于成本优化举措的落 实，毛利率仍同比提升2~3个百分点；于运营方面持续深化精益管理，提升经营效率，令集团经营费用 同比下降约10~11%；及附属公司处置为集团贡献正向收益。 智通财经APP获悉，微创医疗(00853)大涨超11%，截至发稿，涨9.39%，报13.63港元，成交额2.6亿港 元。 ...

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.5917 million shares on January 22, 2026, marking a positive trend in investment interest [1] - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 10.374 million shares [1] - In the last twenty trading days, there have been fifteen days of net increases in holdings, totaling 31.3323 million shares [1] Group 2 - As of January 22, 2026, southbound funds hold a total of 911 million shares of MicroPort Medical, which represents a significant portion of the company's issued ordinary shares [1] - The daily changes in shareholding for the last five trading days show fluctuations, with the largest increase being 4.4877 million shares on January 19, 2026, and a decrease of 2.0648 million shares on January 20, 2026 [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight business segments including cardiovascular intervention, orthopedic medical devices, and surgical robotics [2]